麻黄附子细辛汤联合布地奈德治疗变应性鼻炎的效果评价  

Evaluation of the therapeutic effect of Mahuang Fuzi Xixin decoction combined with Budesonide on allergic rhinitis

在线阅读下载全文

作  者:王国强 Wang Guoqiang(Huimin County Sangluoshu Township Hospital,Shandong,Binzhou,251704,China)

机构地区:[1]惠民县桑落墅镇卫生院,山东滨州251704

出  处:《中国医学文摘(耳鼻咽喉科学)》2025年第1期54-56,59,共4页Chinese Medical Digest(Otorhinolaryngology)

摘  要:目的研究变应性鼻炎(AR)患者行布地奈德+麻黄附子细辛汤治疗效果。方法选择我院2022年1月-2023年1月收治的72例AR患者,“随机取样法”分单一组(布地奈德)、联用组(布地奈德+麻黄附子细辛汤),两组疗效比较。结果用药前分析炎症程度、淋巴细胞亚群无意义,P>0.05;用药后较单一组,联用组IL-4、IL-8指标更低,IL-10、IFN-γ指标更高;CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)值更高,CD8^(+)值更低;症状缓解时间更短;联用组有效率(97.22%)高于单一组(83.33%),P<0.05。结论布地奈德+麻黄附子细辛汤治疗AR患者可减轻炎症程度、调节淋巴细胞亚群,缩短症状缓解时间、增强疗效,值得推崇。Objective To study the therapeutic effect of Budesonide and ephedra aconite and asarum decoction on allergic rhinitis(AR).Methods A total of 72 patients with AR,who were treated in our hospital from January 2022 to January 2010,were randomly 2023 into control group(Budesonide)and Observation Group(Budesonide+Mahuangfuzi Xixin decoction),the curative effect of the two groups was compared.Results The levels of IL-4,IL-8,CD3^(+),CD4^(+)and CD4^(+)/CD8^(+)were significantly lower,and the levels of IL-10,IFN-γ,CD3^(+),CD4^(+)and CD4^(+)/CD8^(+)were significantly higher in the observation group than in the control group before and after treatment,and the levels of IL-4,IL-8,CD3^(+),CD4^(+)and CD4^(+)/CD8^(+)were significantly higher in the observation group than in the control group,the effective rate of Observation Group(97.22%)was higher than that of control group(83.33%),P<0.05.Conclusion Budesonide+Mahuang Fuzi Xixin decoction can reduce the degree of inflammation,regulate the lymphocyte subpopulation,shorten the time of symptom relief and enhance the curative effect in the treatment of AR,which is worthy of praise.

关 键 词:麻黄附子细辛汤 布地奈德 变应性鼻炎 炎症程度 临床疗效 

分 类 号:R28[医药卫生—中药学]

 

参考文献:

正在载入数据...

 

二级参考文献:

正在载入数据...

 

耦合文献:

正在载入数据...

 

引证文献:

正在载入数据...

 

二级引证文献:

正在载入数据...

 

同被引文献:

正在载入数据...

 

相关期刊文献:

正在载入数据...

相关的主题
相关的作者对象
相关的机构对象